Search

Displaying results 3541 - 3550 of 8196 in total
  1. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.

  2. Drug

    Benzylfentanyl

    go.drugbank.com/drugs/DB09182
    ExperimentalIllicit

    Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. … Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.

  3. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastroi...

  4. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  5. Drug

    Mianserin

    go.drugbank.com/drugs/DB06148
    ApprovedWithdrawn

    A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.

    Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 Substrates
  6. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    [A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. … [L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.

  7. Target

    Carbonyl reductases (CBRs)

    go.drugbank.com/bio_entities/BE0010129
    EnzymeHumans

    Component of the heterotetramer complex KAR (3-ketoacyl-[acyl carrier protein] reductase or 3-ketoacyl-[ACP] reductase) that forms part of the mitochondrial fatty acid synthase (mtFAS). … Beta-subunit of the KAR heterotetramer complex, responsible for the 3-ketoacyl-ACP reductase activity of the mtFAS, reduces 3-oxoacyl-[ACP] to (3R)-hydroxyacyl-[ACP] in a NADPH-dependent manner with no

    Synonyms: KAR beta subunit
  8. Drug

    Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10990
    Approved

    Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received

  9. Drug

    Sus scrofa placenta

    go.drugbank.com/drugs/DB14243
    Investigational

    Sus scrofa placenta is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  10. Drug

    Pearl (hyriopsis cumingii)

    go.drugbank.com/drugs/DB14249
    Investigational

    Pearl (hyriopsis cumingii) is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.